RxDoctor Payments DataLook up a doctor →

Islam Al Junaidi, MD

Internal Medicine · Smyrna, DENPI 1891740866

Payments from drug & device makers

$9,576in general payments, 2019–2025

Across 588 payments — averaging $16.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AstraZeneca$1K
  • GSK$963
  • Lilly USA, LLC$819
  • Pfizer$692
  • AbbVie$509
  • plus $4K from 34 others

What the payments were for

  • Food & beverage$9,47199%
  • Education$1041%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,576 in reported general payments places this provider in the 90th percentile of 477 internal medicine providers in Delaware.

See all internal medicine providers in Delaware

Medicare billing

Part B allowed, 2024
$314,496
Medicare patients
505
Services billed
3,284

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide135$211,445
MounjaroTirzepatide85$163,947
RybelsusSemaglutide91$154,258
EliquisApixaban72$73,671
TrulicityDulaglutide27$61,684
Trelegy ElliptaFluticasone/Umeclidin/Vilanter42$30,182
JardianceEmpagliflozin27$29,965
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$19,454
JanuviaSitagliptin Phosphate14$18,893
XareltoRivaroxaban20$16,626
Rosuvastatin Calcium703$15,455
LinzessLinaclotide17$14,047
JanumetSitagliptin Phos/Metformin Hcl12$14,022
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide304$13,354
SynjardyEmpagliflozin/Metformin Hcl22$12,479

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,713$365,703226 claims
Lilly USA, LLCMounjaro, Trulicity$819$225,631112 claims
PfizerEliquis$692$73,67172 claims
Boehringer IngelheimJardiance, Synjardy$432$42,44549 claims
GSKTrelegy Ellipta, Shingrix, Arexvy$963$38,33777 claims
MerckJanuvia, Janumet$165$32,91526 claims
AstraZenecaBreztri Aerosphere, Symbicort$1,174$25,38827 claims
Johnson & JohnsonXarelto$133$16,62620 claims
AbbVieLinzess$509$14,04717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 477 internal medicine providers in Delaware.

Other internal medicine in Smyrna

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →